[en] The report recommends support of research in the methods of production, distribution, biomedical application, and cost effectiveness of a number of accelerator produced and short-lived radionuclides by agencies of the Federal Government. These nuclides, although somewhat difficult to produce and distribute have the potential to provide improved diagnostic information with lower radiation dose when compared to the more conventional radiopharmaceuticals currently in use. Utilizing radioiodine-123 as the principal model and citing new uses for other radionuclides, the report presents information to substantiate a series of recommendations. A brief summary outlines the important forthcoming methodologies which will be required to justify the continuing use of these radionuclides in nuclear medicine and consideration of their growth and benefits